Full trial results of EASE-SBS 1 expected in the third quarter of 2022 Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug Administration The ...
Denmark-based Zealand Pharma A/S ZEAL announced that it has completed enrollment of patients in the pivotal phase III EASE-SBS 1 study that is evaluating its long-acting GLP-2 analog, glepaglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback